10x Genomics (TXG) Receivables - Net (2018 - 2026)

10x Genomics has disclosed Receivables - Net across 9 years of filings, most recently posting $47.5 million for Q2 2026.

• In Q2 2026, Receivables - Net fell 4.87% year-over-year to $47.5 million; the TTM figure through Jun 2026 stood at $47.5 million (down 4.87% YoY), while the FY2025 annual figure was $47.0 million, down 46.49% from the prior year.
• Receivables - Net came in at $47.5 million for Q2 2026 at 10x Genomics, up from $39.0 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $114.8 million in Q4 2023 to a low of $39.0 million in Q1 2026.
• Average Receivables - Net over 5 years is $75.5 million, with a median of $80.7 million recorded in 2023.
• Year-over-year, Receivables - Net soared 33.3% in 2022 and slumped 47.59% in 2025.
• Over 5 years, Receivables - Net stood at $104.2 million in 2022, then increased by 10.19% to $114.8 million in 2023, then declined by 23.49% to $87.9 million in 2024, then tumbled by 46.49% to $47.0 million in 2025, then gained by 1.13% to $47.5 million in 2026.
• Per Business Quant data, the three most recent Receivables - Net figures were $47.5 million in Q2 2026, $39.0 million in Q1 2026, and $47.0 million in Q4 2025.